Capital Counsel LLC Reata Pharmaceuticals Inc Transaction History

Capital Counsel LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$74.57 - $217.92 $1.56 Million - $4.55 Million	-20,900 Reduced 55.15%	17,000 $3.48 Million
Q3 2019 Nov 14, 2019	BUY	$71.26 - $95.75 $634,214 - $852,175	8,900 Added 30.69%	37,900 $3.04 Million
Q2 2019 Aug 14, 2019	SELL	$77.72 - $94.35 $124,352 - $150,960	-1,600 Reduced 5.23%	29,000 $2.74 Million
Q1 2019 May 15, 2019	SELL	$51.9 - $101.79 $114,180 - $223,938	-2,200 Reduced 6.71%	30,600 $2.62 Million
Q3 2018 Nov 14, 2018	SELL	$35.64 - $92.06 $296,453 - $765,755	-8,318 Reduced 20.23%	32,800 $2.68 Million
Q2 2018 Aug 14, 2018	BUY	$19.94 - $40.96 $500,852 - $1.03 Million	25,118 Added 156.99%	41,118 $1.44 Million
Q3 2017 Nov 14, 2017	BUY	$26.29 - $31.88 $420,640 - $510,080	16,000	16,000 $498,000

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Capital Counsel LLC, based on Form 13F filings with the SEC.

Stay updated on Capital Counsel LLC with notifications on news.